personalized / precision medicine

If a tailor made every suit in a single "average" size, most people would get a poor fit. For most of its history, medicine prescribed by the average: the standard dose, the drug that works for most patients with a given diagnosis. Precision medicine is the move toward a tailored fit — choosing the treatment that matches the molecular details of one particular person and their particular disease.

The engine of this shift is molecular data. Instead of treating, say, "breast cancer" as one disease, doctors sequence the tumour's genome and find that it is really several molecularly distinct diseases, each driven by different mutations and each needing a different drug. The same logic reaches healthy people: knowing your DNA can flag inherited risks, and pharmacogenomics can predict how you will metabolize a drug. So "precision" really means stratification — sorting patients into molecularly defined subgroups and matching each group to the therapy most likely to help and least likely to harm, rather than literally inventing a one-off treatment per person.

This is the payoff that ties molecules to medicine: when it works, it spares patients useless drugs and steers them to ones that fit. But three honest cautions matter. Most diseases are complex and polygenic, so for them precision medicine is still more aspiration than reality. Genomic discovery has been done overwhelmingly in people of European ancestry, so its benefits are unevenly distributed — a serious equity problem. And targeted, personalized therapies are often extremely expensive, raising hard questions about who can actually access the medicine of the future.